H. Edward Fleming's most recent trade in Sionna Therapeutics Inc. was a trade of 19,959 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sionna Therapeutics Inc. | H. Edward Fleming | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 19,959 | 19,959 | - | - | Non-Qualified Stock Option (right to buy) | |
| Upstream Bio Inc. | H. Edward Fleming | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 17,096 | 17,096 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | H. Edward Fleming | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Upstream Bio Inc. | Fleming H. Edward | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2024 | 17,096 | 17,096 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | H. Edward Fleming | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | H Edward Fleming | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | H Edward Fleming | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) |